Dectomax 5 mg/ ml Norge - norsk - Statens legemiddelverk

dectomax 5 mg/ ml

zoetis animal health aps - doramektin - påhellingsvæske, oppløsning - 5 mg/ ml

Zepromec 5 mg/ ml Norge - norsk - Statens legemiddelverk

zepromec 5 mg/ ml

chanelle pharmaceuticals manufacturing ltd - eprinomektin - påhellingsvæske, oppløsning - 5 mg/ ml

Apoquel Den europeiske union - norsk - EMA (European Medicines Agency)

apoquel

zoetis belgium sa - oclacitinibmaleat - agenter for dermatitt, unntatt kortikosteroider - hunder - - treatment of pruritus associated with allergic dermatitis in dogs. - treatment of clinical manifestations of atopic dermatitis in dogs.

Dectomax 10 mg/ ml Norge - norsk - Statens legemiddelverk

dectomax 10 mg/ ml

zoetis animal health aps - doramektin - injeksjonsvæske, oppløsning - 10 mg/ ml

Procren Depot 11.25 mg Norge - norsk - Statens legemiddelverk

procren depot 11.25 mg

abbvie as - leuprorelinacetat - pulver og væske til injeksjonsvæske, suspensjon i tokammersprøyte - 11.25 mg

Procren Depot 3.75 mg Norge - norsk - Statens legemiddelverk

procren depot 3.75 mg

abbvie as - leuprorelinacetat - pulver og væske til injeksjonsvæske, suspensjon i tokammersprøyte - 3.75 mg

Procren Depot 30 mg Norge - norsk - Statens legemiddelverk

procren depot 30 mg

abbvie as - leuprorelinacetat - pulver og væske til injeksjonsvæske, suspensjon i tokammersprøyte - 30 mg

Zokinvy Den europeiske union - norsk - EMA (European Medicines Agency)

zokinvy

eigerbio europe limited - lonafarnib - progeria; laminopathies - andre alimentary tract and metabolism products, - zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of hutchinson-gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous lmna mutation with progerin-like protein accumulation or a homozygous or compound heterozygous zmpste24 mutation.

Sutent Den europeiske union - norsk - EMA (European Medicines Agency)

sutent

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Protopic Den europeiske union - norsk - EMA (European Medicines Agency)

protopic

leo pharma a/s - takrolimus - dermatitt, atopisk - andre dermatologiske preparater - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. forekommer fire ganger eller mer per år) som har hatt et første svar til maksimalt seks uker behandling av to ganger daglig takrolimus salve (lesjoner ryddet, nesten ryddet eller mildt rammet).